Market Value367,480,000
Total Holdings51
File Date2021-02-16
Original Filing (Click here)

All hedge funds or institutions that manage over $100M are required by the SEC to file quarterly reports on their holdings. These reports are called 13F reports. However, the filings are required the following quarter from the reporting period, which means that by the time the filing is made (and we see them), the information could be five months old.

For funds with long term positions that make few trades, the holdings might closely resemble their current holdings, even after several months. However, for funds that have high turnover, the holdings data we see might differ significantly from their current holdings. Institutions are required to report CALL and PUT options, and those positions are identified in the table. However, they are not required to report short positions.

Click the link icon to see the full transaction history.

Upgrade to unlock premium data and export to Excel .

Security Imputed
Share Price
Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
(USD x1000)
Current Value
(USD x1000)
Change
(Percent)
KURA / Kura Oncology, Inc.
CCCC / C4 Therapeutics, Inc.
LRMR / Larimar Therapeutics, Inc.
JYAC / Jiya Acquisition Corp - Class A
BHVN / Biohaven Ltd. Call
BCRX / BioCryst Pharmaceuticals, Inc.
CRDF / Cardiff Oncology, Inc.
XBI / SPDR Series Trust - State Street SPDR S&P Biotech ETF Put
VSTM / Verastem, Inc.
VINC / Vincerx Pharma, Inc.
TRIL / Tidal Trust II - Defiance Trillion Dollar Club Index ETF
NUVB / Nuvation Bio Inc.
WVE / Wave Life Sciences Ltd.
RAPT / RAPT Therapeutics, Inc.
ANNX / Annexon, Inc.
KRTX / Karuna Therapeutics, Inc.
CNCE / Concert Pharmaceuticals Inc
AXSM / Axsome Therapeutics, Inc.
MDGL / Madrigal Pharmaceuticals, Inc.
CYCC / Bio Green Med Solution, Inc.
MRSN / Mersana Therapeutics, Inc.
CBIO / Crescent Biopharma, Inc.
SAGE / Sage Therapeutics, Inc.
RNA / Atrium Therapeutics, Inc.
CYTK / Cytokinetics, Incorporated
NUVB.WS / Panacea Acquisition Corp. - Equity Warrant
SURF / Surface Oncology Inc
/ Immunomedics, Inc.
CRIS / Curis, Inc.
STOK / Stoke Therapeutics, Inc.
SELB / Selecta Biosciences Inc
COGT / Cogent Biosciences, Inc.
ALDX / Aldeyra Therapeutics, Inc.
ONCR / Oncorus, Inc.
VTGN / Vistagen Therapeutics, Inc.
BLSA / BCLS Acquisition Corp - Class A
HSAQ / Health Sciences Acquisitions Corp 2
NVAX / Novavax, Inc.
PRAX / Praxis Precision Medicines, Inc.
ISEE / IVERIC bio Inc
CLSD / Clearside Biomedical, Inc.
RLMD / Relmada Therapeutics, Inc.
ATHA / LeonaBio, Inc.
XENE / Xenon Pharmaceuticals Inc.
AVDL / Avadel Pharmaceuticals plc
PMVP / PMV Pharmaceuticals, Inc.
SNDX / Syndax Pharmaceuticals, Inc.
APLS / Apellis Pharmaceuticals, Inc.
ARWR / Arrowhead Pharmaceuticals, Inc.
ALT / Altimmune, Inc.
ETNB / 89bio, Inc.
FDMT / 4D Molecular Therapeutics, Inc.
CLDX / Celldex Therapeutics, Inc.
CBAY / CymaBay Therapeutics, Inc.
IMVT / Immunovant, Inc.
RCKT / Rocket Pharmaceuticals, Inc.
REPL / Replimune Group, Inc.
CMPS / COMPASS Pathways plc - Depositary Receipt (Common Stock)
FULC / Fulcrum Therapeutics, Inc.
IOVA / Iovance Biotherapeutics, Inc.